论文部分内容阅读
维甲酸类药物对多种癌症有效,其作用包括诱导凋亡、抑制生长、促进分化等,这主要通过调节维甲酸受体包括维甲酸受体(retinoic acid receptor,RAR)和维甲酸X受体(rexinoid X receptor,RXR)的表达实现。目前发现,一些患者癌细胞的RAR、RXR或RAR/RXR表达缺乏,可能导致癌细胞对维甲酸产生耐药性。鞘脂代谢异常和维甲酸类受体表达缺失密切相关,在癌细胞对维甲酸产生耐药性中发挥着重要作用。本文就鞘脂代谢异常与维甲酸受体表达异常及维甲酸类药物耐药的相关性做一简要综述。
Retinoids are effective in a variety of cancers and their effects include the induction of apoptosis, inhibition of growth, and promotion of differentiation through the regulation of retinoic acid receptors including the retinoic acid receptor (RAR) and the retinoic acid X receptor (rexinoid X receptor, RXR) expression. It has been found that the lack of expression of RAR, RXR or RAR / RXR in cancer cells of some patients may result in the resistance of cancer cells to retinoic acid. Abnormal sphingolipid metabolism is closely related to the lack of expression of retinoid receptors, and plays an important role in cancer drug resistance to retinoid acid. This article reviews the relationship between abnormal sphingolipid metabolism and retinoic acid receptor expression and the retinoid resistance.